These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12925112)

  • 1. In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities.
    Ioannidou S; Tassios PT; Zachariadou L; Salem Z; Kanelopoulou M; Kanavaki S; Chronopoulou G; Petropoulou N; Foustoukou M; Pangalis A; Trikka-Graphakos E; Papafraggas E; Vatopoulos AC
    Clin Microbiol Infect; 2003 Jul; 9(7):704-7. PubMed ID: 12925112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
    Giovanetti E; Montanari MP; Marchetti F; Varaldo PE
    J Antimicrob Chemother; 2000 Dec; 46(6):905-8. PubMed ID: 11102408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
    Mazzariol A; Koncan R; Bahar G; Cornaglia G
    J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
    Nagai K; Davies TA; Ednie LM; Bryskier A; Palavecino E; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3242-5. PubMed ID: 11600391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.
    Bemer-Melchior P; Juvin ME; Tassin S; Bryskier A; Schito GC; Drugeon HB
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2999-3002. PubMed ID: 11036012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study].
    Gür D; Mülazimoğlu L; Unal S;
    Mikrobiyol Bul; 2007 Jan; 41(1):1-9. PubMed ID: 17427547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro compared activity of telithromycin and azithromycin against northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
    Banche G; Roana J; Allizond V; Andreotti S; Malabaila A; Li Vigni N; Mandras N; Scalas D; Tullio V; Carlone NA; Savoia D; Gaido E; Barbui A; Cuffini AM
    Lett Appl Microbiol; 2008 Oct; 47(4):309-14. PubMed ID: 19241525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae.
    Champney WS; Mentens N; Zurawick K
    Curr Microbiol; 2004 Oct; 49(4):239-47. PubMed ID: 15386111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of antimicrobial and bactericidal activities and postantibiotic effects of macrolides antibiotics against clinical isolates, and examination of shape alteration by scanning electron microscope].
    Yano H; Kobayashi T; Okitsu N; Aoki A; Toriya M; Nakada Y; Sagai H; Iyobe S; Inoue M
    Jpn J Antibiot; 2007 Feb; 60(1):31-46. PubMed ID: 17436861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromcycin versus comparators.
    Shackcloth J; Williams L; Farrell DJ
    J Infect; 2004 Apr; 48(3):229-35. PubMed ID: 15001301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.
    Jalava J; Kataja J; Seppälä H; Huovinen P
    Antimicrob Agents Chemother; 2001 Mar; 45(3):789-93. PubMed ID: 11181362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin.
    Morosini MI; Cantón R; Loza E; del Campo R; Almaraz F; Baquero F
    J Antimicrob Chemother; 2003 Jul; 52(1):50-5. PubMed ID: 12805254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance].
    Gómez-Garcés JL; Alós JI; Hernáiz C; Gómez C
    Enferm Infecc Microbiol Clin; 2004; 22(6):323-7. PubMed ID: 15228898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates.
    Klugman KP; Capper T; Widdowson CA; Koornhof HJ; Moser W
    J Antimicrob Chemother; 1998 Dec; 42(6):729-34. PubMed ID: 10052895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of macrolide-resistance and comparative activity of telithromycin in streptococci in Austria, 1996-2002.
    Buxbaum A; Forsthuber S; Sauermann R; Gattringer R; Graninger W; Georgopoulos A;
    Int J Antimicrob Agents; 2004 Oct; 24(4):397-400. PubMed ID: 15380268
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Flamm RK; Rhomberg PR; Sader HS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased prevalence of erythromycin resistance in streptococci: substantial upsurge in erythromycin-resistant M phenotype in Streptococcus pyogenes (1979-1998) but not in Streptococcus pneumoniae (1985-1999) in Taiwan.
    Hsueh PR; Teng LJ; Lee LN; Yang PC; Ho SW; Lue HC; Luh KT
    Microb Drug Resist; 2002; 8(1):27-33. PubMed ID: 12002646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany.
    Brandt CM; Honscha M; Truong ND; Holland R; Hövener B; Bryskier A; Lütticken R; Reinert RR
    Microb Drug Resist; 2001; 7(2):165-70. PubMed ID: 11442342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates.
    Descheemaeker P; Chapelle S; Lammens C; Hauchecorne M; Wijdooghe M; Vandamme P; Ieven M; Goossens H
    J Antimicrob Chemother; 2000 Feb; 45(2):167-73. PubMed ID: 10660498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.